Reumatologia Clinica最新文献

{"title":"Junta Directiva de la SER, Comité de Organización de Congresos, Comité Científico del Congreso y Comité Organizador Local del Congreso","authors":"","doi":"10.1016/S1699-258X(26)00191-9","DOIUrl":"10.1016/S1699-258X(26)00191-9","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 ","pages":"Pages I-II"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148543397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Índice de autores","authors":"","doi":"10.1016/S1699-258X(26)00197-X","DOIUrl":"10.1016/S1699-258X(26)00197-X","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 ","pages":"Pages S661-S681"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148543395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efecto protector de metotrexato frente a formas graves de COVID-19 en artritis reumatoide: estudio de cohortes retrospectivo","authors":"Freddy Liñán-Ponce ,&nbsp;Juan Leiva-Goicochea ,&nbsp;Fernando Gross-Melo","doi":"10.1016/j.reuma.2026.502160","DOIUrl":"10.1016/j.reuma.2026.502160","url":null,"abstract":"<div><h3>Introduction</h3><div>The COVID-19 pandemic posed a unique challenge for patients with rheumatoid arthritis (RA) receiving immunomodulatory therapy. Methotrexate (MTX), a first-line agent for RA, has pleiotropic effects that may modulate both viral replication and the inflammatory response. This study aimed to determine whether MTX use is associated with a lower incidence of severe or critical COVID-19.</div><div>Material and methods A retrospective cohort study was conducted among patients with a confirmed diagnosis of RA and a documented episode of COVID-19 between 2020 and 2023 at Hospital Víctor Lazarte Echegaray (Trujillo, Peru). Patients with additional autoimmune diseases, neoplasia, pregnancy, significant organ damage, or use of biologic therapy were excluded. Two groups were compared: 207 patients treated with MTX and 155 treated with other conventional disease-modifying antirheumatic drugs. Primary outcomes were severe/critical COVID-19 and 28-day mortality; secondary outcomes included oxygen supplementation, ICU admission, mechanical ventilation, and length of hospitalization.</div></div><div><h3>Results</h3><div>MTX use was associated with a lower frequency of severe/critical COVID-19 (10.6 vs. 22.6%; RR 0.47; 95% CI 0.29-0.77; p<!--> <!-->=<!--> <!-->0.003) and reduced 28-day mortality (1.4 vs. 5.2%; RR 0.27; 95% CI 0.07-0.98; p<!--> <!-->=<!--> <!-->0.041). MTX-treated patients required less supplemental oxygen (16.9 vs. 35.5%; p<!--> <!-->=<!--> <!-->0.001), fewer ICU admissions (4.8 vs. 12.9%) and mechanical ventilation (1.9 vs. 5.8%), and had a shorter median hospital stay (7 vs. 9 days; p<!--> <!-->=<!--> <!-->0.002).</div></div><div><h3>Conclusions</h3><div>Methotrexate use was associated with reduced disease severity, mortality, and hospitalization duration in RA patients with COVID-19. These findings support a potential protective effect of MTX and highlight the need for multicenter prospective studies to confirm its clinical benefit.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 5","pages":"Article 502160"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148003031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comunicaciones orales","authors":"","doi":"10.1016/S1699-258X(26)00192-0","DOIUrl":"10.1016/S1699-258X(26)00192-0","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 ","pages":"Pages S1-S43"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148543390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guía del Colegio Mexicano de Reumatología para el tratamiento farmacológico de la Esclerosis Sistémica Parte 1: Afección cutánea, enfermedad pulmonar intersticial e hipertensión arterial pulmonar","authors":"Karla Chacón-Abril ,&nbsp;Margarita Portela-Hernández ,&nbsp;Luis Daniel Fajardo-Hermosillo ,&nbsp;Leonardo Limón-Camacho ,&nbsp;Natllely Itzel Ruiz-Gómez ,&nbsp;César Pacheco-Tena ,&nbsp;Aarón Alejandro Barrera-Rodríguez ,&nbsp;Olga Vera-Lastra ,&nbsp;Mayra Mejía ,&nbsp;Ivette Buedía-Roldán ,&nbsp;Karen Martínez-Espinosa ,&nbsp;Heidegger Mateos ,&nbsp;Silvia Méndez Flores ,&nbsp;Tomás Pulido-Zamudio ,&nbsp;Nayeli Zayas-Hernández ,&nbsp;José Antonio García-Cuellar ,&nbsp;Dulce Navarro-Vergara ,&nbsp;Jorge Rojas-Serrano ,&nbsp;Gabriel Medrano-Ramírez ,&nbsp;Tatiana S. Rodríguez-Reyna","doi":"10.1016/j.reuma.2026.502164","DOIUrl":"10.1016/j.reuma.2026.502164","url":null,"abstract":"<div><div>Systemic sclerosis (SSc) is a severe autoimmune disease characterized by fibrosis, inflammation, and vasculopathy, with high morbidity and mortality. Cutaneous involvement is an important marker of disease severity, while interstitial lung disease and pulmonary arterial hypertension represent the leading causes of death.</div><div>This manuscript presents the first national pharmacologic treatment guideline, developed using the GRADE methodology and structured around a flexible, stepwise therapeutic algorithm. Unlike international guidelines, this proposal prioritizes clinical applicability and context-specific decision-making, given the heterogeneity of resources and access to treatments within our healthcare system.</div><div>The guideline was developed by a multidisciplinary panel including rheumatologists, dermatologists, pulmonologists, cardiopulmonologists, and methodologists. Authors formulated ten PICO questions, and a systematic search was conducted in PubMed, Cochrane Library, EMBASE, and LILACS (2006–February 2024), including key earlier literature. Of 594 records identified, 114 studies were ultimately included after evaluation using the GRADE methodology. Steroids, immunosuppressants, immunomodulators, hematopoietic stem cell transplantation, and vasodilators were assessed. A total of 26 recommendations were issued and subjected to Delphi consensus, with agreement defined as ≥<!--> <!-->80% acceptance.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 5","pages":"Article 502164"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148003032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deterioro cognitivo en pacientes con artritis reumatoide en relación con la actividad de su enfermedad: un estudio observacional de corte transversal","authors":"Marco Tobar-Marcillo ,&nbsp;Diana Camila Fernández Delgado ,&nbsp;Nathalia Sofía Eraso Muñoz ,&nbsp;Arley Sebastián España Lopez","doi":"10.1016/j.reuma.2026.502167","DOIUrl":"10.1016/j.reuma.2026.502167","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis (RA) is an immune-mediated disease that affects multiple organs. Among its extra-articular manifestations is cognitive impairment (CI).</div></div><div><h3>Methodology</h3><div>This was an observational, cross-sectional study with an analytical approach, including 59<!--> <!-->patients with RA from three specialized outpatient centers in the city of Pasto, Colombia. Data were collected on disease activity using the DAS28 scale, as well as the degree of CI using the Montreal Cognitive Assessment (MoCA).</div></div><div><h3>Results</h3><div>A total of 44.1% of participants were classified as having suspected CI, with lower performance across all assessed subdomains. The most affected domains were visuospatial abilities and language. In the multivariate model, lower educational level was associated with CI, while age, glucocorticoid use, disease activity, and functional disability did not show an independent association.</div></div><div><h3>Conclusion</h3><div>CI has a higher prevalence in patients with RA compared with the general population, with no relationship found between CI and disease activity.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 5","pages":"Article 502167"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148003033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative assessment of interstitial lung disease in rheumatoid arthritis","authors":"Chiara Bertolazzi ,&nbsp;Mario Silva ,&nbsp;Jorge Rojas-Serrano ,&nbsp;Espiridión Ramos-Martínez ,&nbsp;Aldo Carnevale ,&nbsp;Nicolas Sverzellati ,&nbsp;Marwin Gutierrez ,&nbsp;Alfonso Alfaro-Rodriguez ,&nbsp;Alarico Ariani","doi":"10.1016/j.reuma.2026.502159","DOIUrl":"10.1016/j.reuma.2026.502159","url":null,"abstract":"<div><h3>Background</h3><div>Interstitial lung disease (ILD) is the most common pulmonary affection of rheumatoid arthritis (RA). Patients with a severe RA-ILD extent i.e. &gt;20% according to chest Computed Tomography (CT) semiquantitative (SQCT) scores, have poor prognosis. Quantitative CT (QCT) assessment with operator independent methods based on free software represents a reliable solution already tested in other ILD related to rheumatic diseases.</div></div><div><h3>Objectives</h3><div>The main objective of this monocentric study is to verify if in RA-ILD there is a correlation between QCT and SQCT performed by experienced radiologists. Secondary aims are: (a) to explore if there is a difference of QTC indexes (QCTi) in RA-ILD patients with severe vs mild ILD extent; (b) to evaluate the discriminative ability of QCT in identifying severe RA-ILD patients.</div></div><div><h3>Materials and methods</h3><div>The chest CTs of consecutive RA-ILD underwent to a SQCT assessment by two experienced chest radiologists. All CTs were also blindly post-processed by a rheumatologist in order to obtain the QCTi. QCTi correlations, distribution and discriminative ability were, respectively, verified using Spearman rank test, Mann–Whitney test and ROC curves.</div></div><div><h3>Results</h3><div>The majority of QCTi showed a moderate degree (0.40<!--> <!-->&lt;<!--> <em>r</em> <!-->&lt;<!--> <!-->0.59) with SQCT assessment (<em>p</em>-value<!--> <!-->&lt;<!--> <!-->0.01). Patients with severe and mild ILD had dissimilar QCTi values (<em>p</em> <!-->=<!--> <!-->0.001). Almost all of QCTi had a good discriminative ability (AUC from 0.73 to 0.81, <em>p</em>-value<!--> <!-->=<!--> <!-->0.0001).</div></div><div><h3>Conclusions</h3><div>These preliminary findings suggest that RA-ILD extent is related to QCTi. Moreover, QCTi can discriminate very well patients with a severe ILD. So, QCTi may become simple tools quickly estimate RA-ILD prognosis.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 5","pages":"Article 502159"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148003035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Prevalencia de tuberculosis latente en pacientes con enfermedades reumatológicas expuestos a medicamentos biológicos y moléculas pequeñas: un estudio basado en el registro nacional BIOBADAMEX”[Reumatologia Clinica issue 22, Volume 4 (2025)]","authors":"","doi":"10.1016/j.reuma.2026.502212","DOIUrl":"10.1016/j.reuma.2026.502212","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 5","pages":"Article 502212"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148003106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P142-P358","authors":"","doi":"10.1016/S1699-258X(26)00195-6","DOIUrl":"10.1016/S1699-258X(26)00195-6","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 ","pages":"Pages S274-S492"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148543392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P359-P536","authors":"","doi":"10.1016/S1699-258X(26)00196-8","DOIUrl":"10.1016/S1699-258X(26)00196-8","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 ","pages":"Pages S493-S660"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148543394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}